World's Leading Genomic Tests Now Available in India

MUMBAI, August 20, 2015 /PRNewswire/ --

- US-based Myriad Genetics Partners With Positive Bioscience to Offer First-of-its-kind Molecular Genetic Testing in India 

- Aims to Encourage Preventive Healthcare in the Country and Address the Growing Burden of Cancer 

United States-based Myriad Genetics, the world's largest molecular diagnostic company, announced a strategic partnership with Positive Bioscience to offer the first-of-its-kind molecular genomic testing in India.

With the rapid advancement in genomics and testing technologies, clinicians are able to diagnose cancer more precisely and advise their patients about the need for screening or treatment in order to save and improve patient's lives. Genomic testing is still at an early stage in India and this partnership could revolutionize genomics testing in this country.

These tests will help screen for cancer risks and enable families of cancer patients to take various preventive measures. All testing will be carried out at Myriad's high quality labs in USA and Germany.

Hollywood star Angelina Jolie increased public awareness about BRCA genetic mutations by disclosing her test results, her risk for breast and ovarian cancer, and the actions she took to prevent cancer. Myriad Genetics is the world's leading genomics company and was the first to offer BRCA testing for Breast Cancer risk testing. Through this partnership, Positive Bioscience will provide world-class molecular genetic testing for cancer patients and their families. The tests also provide physicians with information to personalize treatment for their cancer patients.

Genomic tests are available for 9 cancers: breast, pancreatic, ovarian, endometrial, melanoma, prostate, colon, lung and gastric.

"We are pleased with our strategic partnership with Positive Bioscience through which Myriad can bring our 25 years of experience in clinical genetic testing to India," said Gary King, Executive Vice-President of International Operations, Myriad Genetics. Gary further added that, "Indian patients can now access world leading tests such as BRACAnalysis^® to identify the risk of developing breast and ovarian cancer, Colaris™ for hereditary colorectal cancer and the myRisk™ test, which assesses the risk of developing eight cancers. Our prognostic tests such as EndoPredict® for breast cancer and Prolaris™ for prostate cancer will help to avoid both the overtreatment and under-treatment of patients and personalize patient care while reducing the economic burden of treatment. We intend to work closely with Positive Bioscience to make these tests available to Indian clinicians and patients."

Speaking on this partnership, Samarth Jain, CEO of Positive Bioscience said, "Positive Bioscience is pleased to work with Myriad to offer molecular genetic testing in India. With our wide reach, thousands of Indians will instantly have access to world-class testing. These tests will help patients by providing insights into potential healthcare challenges they may encounter and improve the quality of their lives."

Through this partnership, Positive Bioscience aims to reach millions of people in the country who are at higher risk of cancer and improve their quality of life.

Tests are available for: 

• Breast cancer patients
• Prostate cancer patients
• Lung cancer patients
• Healthy individuals looking for their own cancer risk and take active measures

About Myriad Genetics 

Myriad Genetics Inc. is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. Myriad Genetics was ranked 16th on the list of the best small companies by Forbes in 2014 for providing cutting edge technologies.

About Positive Bioscience 

Positive Bioscience is a market leader in genomics offering Personal Genomics and Cancer Genomics products. Positive Bioscience aims to make genomic testing technology widely accessible in India. Positive Bioscience's vision is to increase the life expectancy, work towards providing risk assessment for disease occurrence, preventive healthcare and personalized medicine. Positive Bioscience opened India's first Personal Genomics clinic in partnership with Medanta hospital, a landmark event in Indian healthcare. Positive Bioscience additionally operates Personal Genomics clinics in Kokilaben Dhirubhai Ambani hospital and Breach Candy hospital. For more information on how Positive Bioscience is making a difference, please visit: http://www.positivebioscience.com.

For more information, please contact:
The PRactice
Farooque Shaikh
[email protected]
+91-9594777764
Client Operation Lead 2

Disha Sanghavi
[email protected]
+91-9920604558